Patents Assigned to University of Texas Systems
  • Lipocationic dendrimers and uses thereof
    Patent number: 11999683
    Abstract: Modular dendrimers with cationic groups and lipophilic groups are provided herein. In some aspects, the dendrimers provided herein may be formulated in compositions which contain a nucleic acid and one or more helper excipients. In some aspects, these compositions may also be used to treat diseases or disorders with a therapeutic nucleic acid.
    Type: Grant
    Filed: June 15, 2023
    Date of Patent: June 4, 2024
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Daniel J. Siegwart, Kejin Zhou
  • VH4 antibodies and compositions comprising the same
    Patent number: 11999778
    Abstract: The present disclosure in various aspects provides methods for making pharmaceutical compositions for treating neurodegenerative diseases (e.g., demyelinating diseases), such as but not limited to multiple sclerosis, neuromyelitis optica, and transverse myelitis. The pharmaceutical compositions impact specific antibody-mediated processes involved in the biology of neurodegenerative disease. In certain aspects, the disclosure provides pharmaceutical compositions for treating neurodegenerative disease, which are based on inhibiting the action of pathologic antibodies, or alternatively providing antibodies to stimulate neuroprotection or repair processes.
    Type: Grant
    Filed: May 12, 2017
    Date of Patent: June 4, 2024
    Assignee: The Board of Regents of The University of Texas System
    Inventor: Nancy Monson
  • Use of an RXR agonist in treating drug resistant HER2+ cancers
    Patent number: 11998521
    Abstract: The present specification provides combinations of active agents for the improved treatment of Her2+ cancers and associated methods of treatments. The combinations comprise an RXR agonist and a Her2-targeted therapeutic agent and may optionally further comprise thyroid hormone.
    Type: Grant
    Filed: December 7, 2022
    Date of Patent: June 4, 2024
    Assignees: Io Therapeutics, Inc., Board of Regents, The University of Texas System
    Inventors: Martin E. Sanders, Powel H. Brown, Cassandra Moyer, Abhijit Mazumdar
  • CATIONIC SULFONAMIDE AMINO LIPIDS AND AMPHIPHILIC ZWITTERIONIC AMINO LIPIDS
    Publication number: 20240174604
    Abstract: The present disclosure provides one or more amino lipids such as an amino lipids containing a sulfonic acid or sulfonic acid derivative of the formulas: wherein the variables are as defined herein. These amino lipids may be used in compositions with one or more helper lipids and a nucleic acid therapeutic agent. These compositions may be used to treat a disease or disorder such as cancer, cystic fibrosis, or other genetic diseases.
    Type: Application
    Filed: May 10, 2023
    Publication date: May 30, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Daniel J. SIEGWART, Jason B. MILLER
  • STORAGE SOLUTIONS FOR MAINTAINING OF AXONAL VIABILITY
    Publication number: 20240173460
    Abstract: The disclosure relates to defined solutions for organ (heart, liver, kidney, etc,) vascular composite allografts or autografts (VCA: hand, limb, face, etc.) or tissue (peripheral nerves, spinal cord, skin) storage that preserve the electrophysiological functions of axons contained therein. The disclosure also concerns the use of isolated peripheral nerve segments and solid organs preserved in the defined solutions in autograft or allograft transplantation procedures, as well as the use of isolated peripheral nerve segments and solid organs preserved in the defined solutions in autograft/allograft transplantation procedures in combination with the peripheral nerve repair techniques of neurorrhaphy and axonal fusion primarily using polyethylene glycol known as PEG-fusion.
    Type: Application
    Filed: November 20, 2023
    Publication date: May 30, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: George D. BITTNER, David M. JACKSON
  • OX2R Compounds
    Publication number: 20240174685
    Abstract: Methods and compositions for agonizing a type-2 orexin receptor (OX2R) in a cell determined to be in need thereof, including the general method of (a) administering to a subject a cyclic guanidinyl OX2R agonist and (b) detecting a resultant enhanced wakefulness or increased resistance to diet-induced accumulation of body fat, or abbreviated recovery from general anesthesia or jet lag.
    Type: Application
    Filed: February 8, 2024
    Publication date: May 30, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Jef De Brabander, Daniel Rosenbaum, Qiren Liang, Wentian Wang
  • SYSTEM AND METHODS FOR INCREASING SYNTHESIZED PROTEIN STABILITY
    Publication number: 20240177805
    Abstract: A computer-implemented method of training a neural network to improve a characteristic of a protein comprises collecting a set of amino acid sequences from a database, compiling each amino acid sequence into a three-dimensional crystallographic structure of a folded protein, training a neural network with a subset of the three-dimensional crystallographic structures, identifying, with the neural network, a candidate residue to mutate in a target protein, and identifying, with the neural network, a predicted amino acid residue to substitute for the candidate residue, to produce a mutated protein, wherein the mutated protein demonstrates an improvement in a characteristic over the target protein. A system for improving a characteristic of a protein is also described. Improved blue fluorescent proteins generated using the system are also described.
    Type: Application
    Filed: November 28, 2022
    Publication date: May 30, 2024
    Applicant: Board of Regents, The University of Texas System
    Inventors: Andrew Ellington, Austin Cole, Raghav Shroff, Ross Thyer
  • Method of making a neural interface system
    Patent number: 11992319
    Abstract: Neural interfaces with the peripheral nervous system have been developed to provide a direct communication pathway between peripheral nerves and prosthetic limbs. Described herein is a method of making a microchannel integrated neural interface device comprising a plurality of hollow cylindrical electrodes in a PDMS scaffold, which can control the reinnervated muscles and interpret neurological signals. The acquired bioelectrical signals can be used for the interpretation of mind and create a neural map.
    Type: Grant
    Filed: October 25, 2019
    Date of Patent: May 28, 2024
    Assignee: The Board of Regents of The University of Texas System
    Inventors: Paul Yoonsu Choi, Bong Kyun Kim, Bernardo Garza
  • NUCLEOTIDE EDITING TO REFRAME DMD TRANSCRIPTS BY BASE EDITING AND PRIME EDITING
    Publication number: 20240165271
    Abstract: Duchenne muscular dystrophy (DMD) is a fatal muscle disease caused by the lack of dystrophin, which maintains muscle membrane integrity. Provided herein are methods of using adenine base editor (ABE) to modify splice sites of the dystrophin gene, causing skipping or refraining of common DMD exon deletion mutations, restoring dystrophin expression. Also provided herein are methods of using prime editing to reframe the dystrophin open reading frame and restore dystrophin expression.
    Type: Application
    Filed: March 25, 2022
    Publication date: May 23, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Eric N. OLSON, Francesco CHEMELLO, Rhonda BASSEL-DUBY
  • Electrical devices with electrodes on softening polymers and methods of manufacturing thereof
    Patent number: 11991836
    Abstract: An electrical device, comprising a softening polymer layer, an electrode layer on a surface of the softening polymer layer and a cover polymer layer on the surface of the softening polymer layer. An opening in the polymer cover layer is filled with a reflowed solder, one end of the reflowed solder, located inside the opening, contacts a contact pad site portion of the electrode layer, and another end of the reflowed solder contacts an electrical connector electrode of the device.
    Type: Grant
    Filed: January 26, 2023
    Date of Patent: May 21, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Romil Modi, Jonathan Reeder, Gregory T. Ellson, Walter E. Voit, Alexandra Joshi Imre
  • On-line suppressor
    Patent number: 11988649
    Abstract: A device for ion chromatography comprises a tube with an inlet opening and an outlet opening and an inner diameter from about 40 microns to about 10 microns. There is an aperture through one side of the tube into a lumen of the tube. At least a portion of the inner surface of the tube has a first charge. An ion exchange barrier covers the aperture on an outside surface of the tube. The inner surface of the tube, from the inlet opening to the aperture, is coated with ion exchange particles having a diameter ranging from about 30 nm to about 200 nm. The ion exchange particles have a second charge opposite the first charge. The inner surface of the tube, from the outlet opening to the aperture, is not coated with ion exchange particles.
    Type: Grant
    Filed: October 6, 2020
    Date of Patent: May 21, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Purnendu K. Dasgupta, Bikash Chouhan, Joseph Ray
  • Method of reconstituting liposomal annamycin
    Patent number: 11980634
    Abstract: Methods of reconstituting lyophilized Annamycin and methods of treating patients are described.
    Type: Grant
    Filed: October 5, 2023
    Date of Patent: May 14, 2024
    Assignees: Moleculin Biotech, Inc., Board of Regents, The University of Texas System
    Inventors: Donald Picker, Waldemar Priebe
  • METHODS AND SYSTEMS FOR ANALYZING BRAIN LESIONS FOR THE DIAGNOSIS OF MULTIPLE SCLEROSIS
    Publication number: 20240153091
    Abstract: Some methods comprise, for each of one or more lesions of a patients brain, from data taken at first and second times, determining two or more lesion characteristics including a lesion's volume change and whether the lesion moved toward a center of the brain. Some methods comprise, for each lesion, determining whether one or more criteria are satisfied, including a volume-and-displacement-based criterion that is satisfied when the change in the volume of the lesion is less than zero and the lesion moved toward the brain's center or the change in the volume of the lesion is greater than zero and the lesion did not move toward the brain's center. Some methods comprise characterizing whether the patient has multiple sclerosis and/or the progression, regression, or stability of multiple sclerosis based at least in part on the assessment of the one or more criteria for each of the lesion(s).
    Type: Application
    Filed: March 8, 2022
    Publication date: May 9, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventor: Darin T. OKUDA
  • COMPOSITIONS AND METHODS FOR ORGAN SPECIFIC DELIVERY OF NUCLEIC ACIDS
    Publication number: 20240148666
    Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.
    Type: Application
    Filed: December 11, 2023
    Publication date: May 9, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: Qiang CHENG, Tuo WEI, Daniel J. SIEGWART
  • Human PD-L2 antibodies and methods of use therefor
    Patent number: 11976128
    Abstract: The present disclosure is directed to antibodies binding to PD-L2 and methods of using such antibodies to treat cancers, such as those that express or overexpress PD-L2.
    Type: Grant
    Filed: March 15, 2019
    Date of Patent: May 7, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Michael A. Curran, Ashvin R. Jaiswal, Dongxing Zha, Kui Voo, Carlo Toniatti, Bianka Prinz, Nadthakarn Boland
  • Spintronic computing architecture and method
    Patent number: 11977970
    Abstract: The present disclosure provides a domain wall magnetic tunnel junction device. Integration of input spikes pushes a domain wall within a ferromagnetic track toward a magnetic tunnel junction (MTJ). An energy gradient within the track pushes the domain wall away from the MTJ by leaking accumulated energy from the input spikes. If the integrated input spikes exceed the energy leak of the gradient within a specified time period, the domain wall reaches the MTJ and reverses its resistance, producing an output spike. The leaking energy gradient can be created by a magnetic field, a trapezoidal shape of the ferromagnetic track, or nonuniform material properties in the ferromagnetic track. A feedback and feedforward crossbar configuration is disclosed that provides for a neuromorphic computing system suitable for unsupervised learning.
    Type: Grant
    Filed: March 24, 2021
    Date of Patent: May 7, 2024
    Assignee: Board of Regents, The University of Texas System
    Inventors: Joseph S. Friedman, Wesley H. Brigner, Naimul Hassan, Xuan Hu, Alvaro Velasquez
  • ALLELE SELECTIVE INHIBITION OF MUTANT C9ORF72 FOCI EXPRESSION BY DUPLEX RNAS TARGETING THE EXPANDED HEXANUCLEOTIDE REPEAT
    Publication number: 20240141348
    Abstract: Provided herein are compositions and methods for reducing expression of C9orf72 transcripts in cells containing expanded intronic GGGGCC regions, including those in subjects having or at risk of developing amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD).
    Type: Application
    Filed: October 19, 2023
    Publication date: May 2, 2024
    Applicant: The Board of Regents of The University of Texas System
    Inventors: David COREY, Jiaxin HU
  • METHODS FOR TREATMENT OF POLYCYSTIC KIDNEY DISEASE
    Publication number: 20240141350
    Abstract: Provided herein are methods for the treatment of polycystic kidney disease, including autosomal dominant polycystic kidney disease, using modified oligonucleotides targeted to miR-17.
    Type: Application
    Filed: November 30, 2023
    Publication date: May 2, 2024
    Applicants: Regulus Therapeutics Inc., The Board of Regents of The University of Texas System
    Inventors: Charles R. ALLERSON, Vishal D. PATEL, B. Nelson CHAU, John R. ANDROSAVICH
  • Methods and compositions for antimicrobial treatment
    Patent number: 11969511
    Abstract: Various embodiments disclosed relate to methods and compositions for antimicrobial treatment. In various embodiments, the present invention provides a method of antimicrobial treatment. The method includes at least one of exposing at least one microbe to a magnetic field, and contacting the at least one microbe with at least one nanoparticle including iron.
    Type: Grant
    Filed: September 3, 2021
    Date of Patent: April 30, 2024
    Assignees: UNM Rainforest Innovations, Board of Regents, The University of Texas System
    Inventors: Marek A. Osinski, Hugh D. C. Smyth, Leisha Marie Armijo, Hennaka Mudiyanselage Herath Nihal Bandara
  • Antibodies and molecules that immunospecifically bind to BTN1A1 and the therapeutic uses thereof
    Patent number: 11970534
    Abstract: Provided herein are molecules having an antigen binding fragment that immunospecifically binds to BTN1A1, such as anti-BTN1A1 antibodies. These molecules include those having an antigen binding fragment that immunospecifically binds to glycosylated BTN1A1, such as anti-glycosylated BTN1A1 antibodies. Methods of making and using these molecules are also provided, including methods of using them in cancer therapies, or as cancer diagnostics.
    Type: Grant
    Filed: November 24, 2020
    Date of Patent: April 30, 2024
    Assignees: STCUBE & CO., INC., Board of Regents, The University of Texas System
    Inventors: Stephen Sunghan Yoo, Michael Joseph Surace, Steven Hsesheng Lin, Amrish Sharma